India’s revised Uniform Code for Pharmaceutical Marketing Practices (UCPMP) has widened disclosure requirements for industry’s interactions with healthcare professionals and laid down a framework for continuing medical education (CME) programs that includes enabling provisions for an audit of these initiatives.
‘Unsavoury’ Practices: Pharma Will Need To Be More Transparent On CME Expenses In India
Faces Audits Under Revised Rules
India’s revised code for marketing practices includes US Sunshine Act-like requirements converging with tax laws and puts the spotlight on continuing medical education initiatives, where pharma will need to display funding/expenditure data on their website. The Pink Sheet talks to experts on the implications and also new requirements on brand reminders and drug samples.
More from India
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
US President Trump’s plan for a “25% or higher” tariff on pharmaceuticals promises to have a far-reaching impact, from higher prices and drug shortages to increased onshoring of manufacturing in the US. Is MAGA worth the chaos it might create for MAHA? The Indian industry shares its views.
• By
Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader talk about compliance requirements that pharma and global capability centers may need to consider as India strengthens the framework for the protection of digital personal data.
• By
Faster approvals and regulatory flexibility are among moves India has made to draw clinical trial investments. As MNCs seek to replace products close to patent expiry with new blockbusters and domestic companies tap unmet needs, how will the R&D landscape shape up in 2025?
More from Asia
• By
The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.
• By
Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.
• By
A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.